The special drug use-results survey (All-Case Surveillance) of OfevĀ® Capsules in patients with Idiopathic Pulmonary Fibrosis (IPF) in Japan

08/09/2015
21/10/2026
EU PAS number:
EUPAS10891
Study
Finalised
Study type

Study topic

Human medicinal product

Study type

Non-interventional study

Scope of the study

Effectiveness study (incl. comparative)
Safety study (incl. comparative)

Data collection methods

Primary data collection
Non-interventional study

Non-interventional study design

Cohort
Other

Non-interventional study design, other

Prospective, observational, single arm
Study drug and medical condition

Medicinal product name

Study drug International non-proprietary name (INN) or common name

NINTEDANIB

Anatomical Therapeutic Chemical (ATC) code

(L01EX09) nintedanib
nintedanib

Medical condition to be studied

Idiopathic pulmonary fibrosis
Population studied

Short description of the study population

Patients with Idiopathic Pulmonary Fibrosis (IPF) in Japan

Age groups

  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

5.200
Study design details

Study design

Non-interventional study

Main study objective

To evaluate the real-world safety and effectiveness of Ofev Capsules treatment in patients with IPF

Outcomes

The frequency of patients with any suspected adverse drug reactions, The absolute change from the baseline in Forced Vital Capacity (FVC) mL at Week 104.

Data analysis plan

Analyses are descriptive in nature including means, standard deviation, Q1, medians, Q3, frequency and percentages. For safety outcomes, incidence rates with corresponding 95% confidence intervals will also be calculated. For the effectiveness outcomes, the point estimate and 95% confidence intervals from statistical models will also be calculated for exploratory purpose.

Summary results

There was no notable difference in major safety profile between the results from PMS study and the information provided in the Japanese package insert. The study does not indicate any changes on Risk and Benefit
concerning with Ofev Capsules treatment.